Fig. 5.

Neoantigen reprioritization based on RNA-seq and vaccination screening studies. a Out of 24 predicted neoantigens for clone E, 13 were validated to be immunogenic through vaccination studies which generated a T cell response measured by IFN-ϒ ELISpot assay. Mice (n = 5/group) were vaccinated with Poly ICLC alone or Poly ICLC + neoantigen peptides on days 0, and 7. The spleens were harvested on Day 13 and ELISpot assay was performed. b Sample ELISpot wells from vaccination experiments. Data are combined from multiple separate experiments. Wells shown are representative triplicates or duplicates of a single mouse. c SLP vaccination with 13 immunogenic neoantigens for clone E in the prophylactic setting restrains tumor growth after subcutaneous inoculation